In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

Novavax performed well last year, but the company's shares are down significantly over the past three years and are not far ...

Staff and funding cuts to the NIH, FDA and USAID could have downstream implications for R&D in the pharma industry, experts ...

Initial phase III trial results from November 2020 suggested that, after two doses, new mRNA vaccines developed by Moderna ...

Local public health officials are the front line for responding to any disease outbreak. Five years after the coronavirus pandemic began, many say that the entrenched politicization of COVID-19 has ...